PRC2 Inhibition Enables Self-Renewal of Chimpanzee Naive PSCs

Study Background and Research Question

Pluripotent stem cells (PSCs) in the naive state correspond to the earliest, most undifferentiated phase of embryonic development. While mouse and human naive PSCs have been successfully derived and maintained, equivalent lines from non-human primates have remained challenging to establish. This limitation has restricted comparative studies of pluripotency and early embryogenesis between humans and our closest evolutionary relatives. A central obstacle is the inability of reprogrammed or "reset" chimpanzee PSC colonies to propagate in vitro, suggesting a species-specific barrier to naive state self-renewal. Huang et al. (2025) addressed whether epigenetic repression, particularly by Polycomb repressive complex 2 (PRC2), underlies this barrier, and if so, whether its inhibition could enable stable expansion of naive PSCs from chimpanzee (Huang et al., 2025).

Key Innovation from the Reference Study

The central innovation of this study is the identification of excess deposition of the repressive histone modification H3K27me3—catalyzed by PRC2—as a primary roadblock to chimpanzee naive PSC self-renewal. By pharmacologically inhibiting PRC2 activity, the authors were able to support robust, feeder-free in vitro expansion of naive PSCs from chimpanzee embryos. This breakthrough not only establishes a new primate model for early embryonic pluripotency but also reveals a conserved, yet previously underappreciated, role for chromatin modification in regulating stem cell identity.

Methods and Experimental Design Insights

Huang and colleagues employed a combination of chemical inhibition and genetic manipulation to interrogate the role of PRC2 in naive PSC maintenance. Initial attempts to generate chimpanzee naive PSCs via reprogramming and culture in conditions optimized for human and mouse naive PSCs resulted in colonies that failed to propagate. The researchers then applied a small-molecule PRC2 inhibitor, which specifically targets the complex’s catalytic subunit, EZH2, responsible for H3K27 trimethylation.

Transcriptomic profiling was performed to assess the similarity of expanded chimpanzee naive PSCs to human naive PSCs and to pre-implantation epiblast. Differentiation assays tested the ability of these cells to form blastoids—three-dimensional structures mimicking the blastocyst stage and containing all expected cell lineages (epiblast, trophectoderm, and hypoblast). Genetic deletion experiments of key PRC2 components further confirmed the mechanistic role of PRC2-mediated repression in growth arrest.

Protocol Parameters

• PRC2 inhibition: Continuous exposure to a selective EZH2 inhibitor during cell culture to maintain naive PSC identity.
• Feeder-free propagation: Culturing naive PSCs on defined substrates in the presence of PRC2 inhibitor supports expansion without feeder cells.
• Validation assays: Transcriptome profiling, pluripotency marker expression, and in vitro differentiation to blastoids for functional assessment.
• Genetic controls: Targeted deletion of PRC2 subunits to confirm dependency of self-renewal on PRC2 inhibition.

Core Findings and Why They Matter

The study’s pivotal finding is that PRC2-mediated H3K27me3 deposition is a conserved barrier to naive PSC self-renewal in chimpanzee, analogous to constraints observed in certain human PSC culture conditions. Inhibition of PRC2 activity enabled not only robust expansion and maintenance of chimpanzee naive PSCs but also their differentiation into blastoids, recapitulating lineage specification observed in early embryos. Transcriptomic analyses revealed high similarity between chimpanzee and human naive PSCs, providing a powerful comparative platform for studying primate development and evolutionary divergence (Huang et al., 2025).

Importantly, the study also demonstrated that PRC2 inhibition facilitates feeder-free propagation of human naive PSCs, highlighting broader translational relevance in stem cell biology. These insights enhance our understanding of how chromatin regulation impacts pluripotency and may inform new strategies for stem cell derivation across species.

Comparison with Existing Internal Articles

While most existing literature and practical resources focus on the role of EZH2 inhibitors such as GSK126 in cancer epigenetics research, particularly in lymphoma with EZH2 mutations and small cell lung cancer research, the work by Huang et al. extends the application of PRC2 inhibition into the domain of developmental and comparative stem cell biology. Internal articles, such as "GSK126: Transforming Cancer Epigenetics Through Precision..." and "GSK126 (EZH2 Inhibitor): Precision Tool for Cancer Epigen...", primarily discuss the impact of selective EZH2/PRC2 inhibition in oncology drug development and gene silencing workflows. These resources provide valuable mechanistic perspectives and protocol optimization for using GSK126 in cancer models, where PRC2 inhibition leads to reactivation of silenced tumor suppressor genes and increased sensitivity to chemotherapy.

The reference study complements this by demonstrating the utility of PRC2 inhibition in a non-oncogenic context—enabling the propagation of naive PSCs for developmental studies. This underscores the broader importance of small molecule EZH2 inhibitors in modulating epigenetic states beyond cancer, supporting both fundamental and translational research agendas.

Limitations and Transferability

Several considerations temper the direct transferability of these findings. First, while PRC2 inhibition was effective in enabling chimpanzee and, to a lesser extent, human naive PSC propagation, its long-term effects on genetic and epigenetic stability require further investigation. The study was conducted under controlled in vitro conditions using defined small molecule inhibitors; the extent to which these results translate to other primate species or to in vivo contexts is not yet established. Additionally, the precise choice and concentration of PRC2 inhibitor, as well as potential off-target effects, should be carefully evaluated in future experiments.

Research Support Resources

Researchers aiming to replicate or extend these protocols can employ validated selective EZH2 inhibitors to inhibit PRC2 function and reduce H3K27me3 deposition. GSK126 EZH2 inhibitor (SKU A3446) is a potent and selective small molecule inhibitor widely used in epigenetic regulation studies, including PRC2-dependent gene silencing and reprogramming workflows. According to product information, GSK126 binds EZH2 with high affinity and is effective at concentrations typically ranging from 0.5 to 8 μM, supporting both short-term and extended culture paradigms. For detailed guidance on experimental design and troubleshooting, practical workflow recommendations can be found in internal resources such as "GSK126 (EZH2 inhibitor): Practical Solutions for Reproduc...". APExBIO supplies GSK126 for laboratory research use. Proper storage and handling are recommended to maintain compound stability during extended protocols.